• Je něco špatně v tomto záznamu ?

p19-targeted ABD-derived protein variants inhibit IL-23 binding and exert suppressive control over IL-23-stimulated expansion of primary human IL-17+ T-cells

L. Křížová, M. Kuchař, H. Petroková, R. Osička, M. Hlavničková, O. Pelák, J. Černý, T. Kalina, P. Malý,

. 2017 ; 50 (2) : 102-113. [pub] 20170119

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18016800

Grantová podpora
NV16-27676A MZ0 CEP - Centrální evidence projektů

Interleukin-23 (IL-23), a heterodimeric cytokine of covalently bound p19 and p40 proteins, has recently been closely associated with development of several chronic autoimmune diseases such as psoriasis, psoriatic arthritis or inflammatory bowel disease. Released by activated dendritic cells, IL-23 interacts with IL-23 receptor (IL-23R) on Th17 cells, thus promoting intracellular signaling, a pivotal step in Th17-driven pro-inflammatory axis. Here, we aimed to block the binding of IL-23 cytokine to its cell-surface receptor by novel inhibitory protein binders targeted to the p19 subunit of human IL-23. To this goal, we used a combinatorial library derived from a scaffold of albumin-binding domain (ABD) of streptococcal protein G, and ribosome display selection, to yield a collection of ABD-derived p19-targeted variants, called ILP binders. From 214 clones analyzed by ELISA, Western blot and DNA sequencing, 53 provided 35 different sequence variants that were further characterized. Using in silico docking in combination with cell-surface competition binding assay, we identified a group of inhibitory candidates that substantially diminished binding of recombinant p19 to the IL-23R on human monocytic THP-1 cells. Of these best p19-blockers, ILP030, ILP317 and ILP323 inhibited IL-23-driven expansion of IL-17-producing primary human CD4+ T-cells. Thus, these novel binders represent unique IL-23-targeted probes useful for IL-23/IL-23R epitope mapping studies and could be used for designing novel p19/IL-23-targeted anti-inflammatory biologics.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016800
003      
CZ-PrNML
005      
20180515103506.0
007      
ta
008      
180515s2017 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/08916934.2016.1272598 $2 doi
035    __
$a (PubMed)28100093
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Křížová, Lucie $u a Laboratory of Ligand Engineering , Institute of Biotechnology, Czech Academy of Sciences, v. v. i, BIOCEV Research Center , Vestec , Czech Republic.
245    10
$a p19-targeted ABD-derived protein variants inhibit IL-23 binding and exert suppressive control over IL-23-stimulated expansion of primary human IL-17+ T-cells / $c L. Křížová, M. Kuchař, H. Petroková, R. Osička, M. Hlavničková, O. Pelák, J. Černý, T. Kalina, P. Malý,
520    9_
$a Interleukin-23 (IL-23), a heterodimeric cytokine of covalently bound p19 and p40 proteins, has recently been closely associated with development of several chronic autoimmune diseases such as psoriasis, psoriatic arthritis or inflammatory bowel disease. Released by activated dendritic cells, IL-23 interacts with IL-23 receptor (IL-23R) on Th17 cells, thus promoting intracellular signaling, a pivotal step in Th17-driven pro-inflammatory axis. Here, we aimed to block the binding of IL-23 cytokine to its cell-surface receptor by novel inhibitory protein binders targeted to the p19 subunit of human IL-23. To this goal, we used a combinatorial library derived from a scaffold of albumin-binding domain (ABD) of streptococcal protein G, and ribosome display selection, to yield a collection of ABD-derived p19-targeted variants, called ILP binders. From 214 clones analyzed by ELISA, Western blot and DNA sequencing, 53 provided 35 different sequence variants that were further characterized. Using in silico docking in combination with cell-surface competition binding assay, we identified a group of inhibitory candidates that substantially diminished binding of recombinant p19 to the IL-23R on human monocytic THP-1 cells. Of these best p19-blockers, ILP030, ILP317 and ILP323 inhibited IL-23-driven expansion of IL-17-producing primary human CD4+ T-cells. Thus, these novel binders represent unique IL-23-targeted probes useful for IL-23/IL-23R epitope mapping studies and could be used for designing novel p19/IL-23-targeted anti-inflammatory biologics.
650    _2
$a buněčné linie $7 D002460
650    _2
$a dendritické buňky $x imunologie $x metabolismus $7 D003713
650    _2
$a lidé $7 D006801
650    _2
$a interleukin-23 $x chemie $x metabolismus $7 D053759
650    _2
$a interleukin-23 - podjednotka p19 $x chemie $x metabolismus $x farmakologie $7 D053760
650    _2
$a aktivace lymfocytů $x imunologie $7 D008213
650    _2
$a makrofágy $x imunologie $x metabolismus $7 D008264
650    _2
$a molekulární modely $7 D008958
650    _2
$a fagocyty $x imunologie $x metabolismus $7 D010586
650    _2
$a vazba proteinů $7 D011485
650    _2
$a konformace proteinů $7 D011487
650    _2
$a receptory interleukinů $x metabolismus $7 D018123
650    _2
$a rekombinantní proteiny $7 D011994
650    _2
$a signální transdukce $7 D015398
650    _2
$a T-lymfocyty - podskupiny $x imunologie $x metabolismus $7 D016176
650    _2
$a buňky Th17 $x imunologie $x metabolismus $7 D058504
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kuchař, Milan $u a Laboratory of Ligand Engineering , Institute of Biotechnology, Czech Academy of Sciences, v. v. i, BIOCEV Research Center , Vestec , Czech Republic.
700    1_
$a Petroková, Hana $u a Laboratory of Ligand Engineering , Institute of Biotechnology, Czech Academy of Sciences, v. v. i, BIOCEV Research Center , Vestec , Czech Republic.
700    1_
$a Osička, Radim $u b Laboratory of Molecular Biology of the Bacterial Pathogens , Institute of Microbiology, Czech Academy of Sciences , Prague , Czech Republic.
700    1_
$a Hlavničková, Marie $u a Laboratory of Ligand Engineering , Institute of Biotechnology, Czech Academy of Sciences, v. v. i, BIOCEV Research Center , Vestec , Czech Republic.
700    1_
$a Pelák, Ondřej $u c CLIP, Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol , Prague , Czech Republic , and.
700    1_
$a Černý, Jiří $u d Laboratory of Biomolecular Recognition , Institute of Biotechnology, Czech Academy of Sciences, v. v. i, BIOCEV Research Center , Vestec , Czech Republic.
700    1_
$a Kalina, Tomáš $u c CLIP, Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol , Prague , Czech Republic , and.
700    1_
$a Malý, Petr $u a Laboratory of Ligand Engineering , Institute of Biotechnology, Czech Academy of Sciences, v. v. i, BIOCEV Research Center , Vestec , Czech Republic.
773    0_
$w MED00000637 $t Autoimmunity $x 1607-842X $g Roč. 50, č. 2 (2017), s. 102-113
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28100093 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180515103640 $b ABA008
999    __
$a ok $b bmc $g 1300424 $s 1013640
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 50 $c 2 $d 102-113 $e 20170119 $i 1607-842X $m Autoimmunity $n Autoimmunity $x MED00000637
GRA    __
$a NV16-27676A $p MZ0
LZP    __
$a Pubmed-20180515

Najít záznam

Citační ukazatele

Možnosti archivace